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ABSTRACT Trachoma is initiated during childhood following repeated conjunctival
infection with Chlamydia trachomatis, which causes a chronic inflammatory response
in some individuals that leads to scarring and in-turning of the eyelids in later life.
There is currently no treatment to halt the progression of scarring trachoma due to
an incomplete understanding of disease pathogenesis. A cohort study was per-
formed in northern Tanzania in 616 children aged 6 to 10 years at enrollment. Every
3 months for 4 years, children were examined for clinical signs of trachoma, and
conjunctival swabs were collected for C. trachomatis detection and to analyze the
expression of 46 immunofibrogenic genes. Data were analyzed in relation to pro-
gressive scarring status between baseline and the final time point. Genes that were
significantly associated with scarring progression included those encoding proinflamma-
tory chemokines (CXCL5, CCL20, CXCL13, and CCL18), cytokines (IL23A, IL19, and IL1B),
matrix modifiers (MMP12 and SPARCL1), immune regulators (IDO1, SOCS3, and IL10), and
a proinflammatory antimicrobial peptide (S100A7). In response to C. trachomatis infec-
tion, IL23A and PDGF were significantly upregulated in scarring progressors relative to in
nonprogressors. Our findings highlight the importance of innate proinflammatory signals
from the epithelium and implicate interleukin 23A (IL-23A)-responsive cells in
driving trachomatous scarring, with potential key mechanistic roles for PDGFB,
MMP12, and SPARCL1 in orchestrating fibrosis.
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Trachoma is a neglected tropical disease and the leading infectious cause of blind-ness worldwide. Disease is initiated by repeated infection of the conjunctival
epithelium by the intracellular bacterium Chlamydia trachomatis, which occurs during
childhood in areas where trachoma is endemic. Ocular C. trachomatis infection stimu-
lates a chronic pathological inflammatory response in a proportion of exposed indi-
viduals, which leads to scarring of the conjunctiva. Conjunctival fibrosis tightens the
eyelid, drawing inwards the lid margin (entropion) and eyelashes (trichiasis) such that
they cause mechanical damage to the cornea. Without intervention (epilation of the
lashes or surgery to correct lid orientation) this damage results in pain, secondary
infection, and ultimately blindness. In 2017, 165 million people lived in districts requiring
public health interventions for trachoma and 231,447 people worldwide were managed
for trichiasis (1).
Mass antibiotic distribution with azithromycin is administered for population control
of C. trachomatis in districts requiring intervention, alongside facial cleanliness promo-
tion and environmental improvements to reduce transmission. However, scarring
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disease progresses in previously exposed individuals in the absence of evidence of
ongoing C. trachomatis infection, suggesting that service provision for trichiasis man-
agement will be required for many years in districts where it was formerly endemic (2,
3). There is currently no treatment to halt the progression of established scarring, partly
due to an incomplete understanding of the immunopathophysiological process.
Following pathogen recognition and initiation of inflammation by the conjunctival
epithelium, an adaptive immune cell-mediated response involving Th1 cells, classically
activated macrophages, and gamma interferon (IFN-) is believed to be essential to
clear ocular C. trachomatis infection (4–6). NK cells are an additional source of IFN-, and
there is evidence that Th17 cells and associated cytokines are involved in the antichla-
mydial immune response (4, 7, 8). Following pathogen clearance, there is an extended
period of inflammation and wound healing, which is thought to be characterized by the
presence and activity of neutrophils and growth and matrix factors and by a reduction
in the expression of mucin genes (4, 8). These data have been gathered almost entirely
from cross-sectional studies, and, as a result, the factors driving healthy wound healing
versus pathological inflammation and fibrosis have not been differentiated.
We recently reported the results of a cohort study that investigated the association
between conjunctival C. trachomatis infection and clinically visible inflammatory epi-
sodes with scarring progression in children over a 4-year period (9). The study took
place from 2012 to 2016 in a region of northern Tanzania where trachoma is endemic.
Scarring progression was observed in 103/448 (23%) individuals and was strongly
associated with an increasing proportion of episodes with papillary inflammation (TP)
(equivalent to P2 or P3 of the Detailed WHO Trachoma Grading System [2]). There were
also marginal associations between “trachomatous inflammation—follicular” (TF) and C.
trachomatis with scarring progression, which were shown to be mediated through TP.
This suggests that other factors causing individual differences in TP contributed to
scarring progression. However, the immune mediators driving TP and their cellular
origins are unknown.
The aim of this study was to determine which components of the inflammatory
response were most strongly associated with 4-year scarring progression and patho-
logical TP. We further examined whether individuals with scarring progression re-
sponded differently at the gene expression level to C. trachomatis infection relative to
nonprogressors.
RESULTS
A detailed description of the longitudinal study design and primary outcomes has
been published elsewhere (4, 9, 10). Briefly, of the 666 eligible children, 616 were
enrolled in the cohort study. Of these, 448 remained in the primary outcome analysis
of factors associated with 4-year scarring progression. Scarring progression was ob-
served in 23% (103/448) of individuals and was associated with increasing proportion
of TP episodes. Gene expression was analyzed at study time points 1 to 5, 7, 9, 11, 13,
15, and 17. The number of participants seen at each time point and the number in
which C. trachomatis and TP were detected are shown in Table 1. In addition to the
endogenous control genes HPRT1 and GAPDH, 46 genes of interest were quantified in
all available samples at each of these time points. Three genes (FGF2, SERPINB4-
SERPINB3, and IL22) and 61 observations were excluded from all analyses due to 10%
missing data.
The association between gene expression and scarring progression was analyzed
using random effects logistic regression models of the longitudinal data, clustering on
participant identification number and adjusting for C. trachomatis infection, age, and
sex. Of the 10 genes most strongly associated with 4-year scarring progression, only
SPARCL1 (fold change [FC] 0.54; P 1.36 105) was downregulated in scarring
progressors, whereas CXCL5, SOCS3, IL23A, IL19, CCL20, IDO1, MMP12, S100A7, and IL1B
were upregulated (Table 2). All upregulated genes had marginal fold changes of less
than 1.4. With the exception of NCAM1, there was strong evidence that expression of
all genes was altered with C. trachomatis infection (Table 2). The three most strongly
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upregulated genes (FC 5) in response to infection were IFNG, IL21, and CCL18, and the
three most strongly downregulated genes (FC 0.32) were MUC7, MUC5AC, and
SPARCL1. There was evidence of an association between 20 genes and sex; 16 of these
genes were upregulated in females. The top three genes most strongly associated with
female sex were IL21, IL17A, and IFNG. Evidence was found for an association between
age and all genes except ALOX5, CD247, IL12B, VIM, PDGFB, and TGFB1. Out of the genes
associated with age, the majority (29/37) had negative fold changes, indicating that
expression was higher in younger participants.
To further examine the genes most strongly associated with scarring progression,
random effects lasso regression was performed in the longitudinal data set, clustering
on participant identifier (ID). After filtering out incomplete cases, 3,622 observations
remained in the analysis. In addition to genes associated with sex and age, the final
iteration of the model retained 11 genes deemed to be most strongly associated with
scarring progression, namely, SPARCL1, CXCL13, CCL18, CCL20, IL10, MMP12, IDO1, IL23A,
S100A7, CXCL5, and IL19. All of these targets were also identified as strongly associated
with scarring progression in the linear regression models (Table 2), whereas CXCL13,
CCL18, and IL10 were additionally identified by the lasso regression only.
Prior analysis of the cohort data set indicated that the marginal association between
C. trachomatis infection and 4-year scarring progression was mediated through TP,
suggesting that an individual’s response to infection—rather than simply the presence
or absence of infection alone—determines their risk of scarring sequelae (9). In order
to investigate this further, random effects regression models were performed for each
gene in turn; these included an interaction term between scarring progression status
and C. trachomatis infection in order to determine whether scarring progressors
responded differently to infection relative to nonprogressors. Two genes, PDGFB and
IL23A, showed some evidence of being upregulated in response to C. trachomatis
infection by a greater amount in progressors than in nonprogressors (Table 3). In
scarring progressors PDGFB was upregulated 1.58-fold in response to infection, whereas
it was upregulated 1.31-fold in nonprogressors. Similarly, IL23A was upregulated 2.33-
fold in response to infection in scarring progressors and 1.77-fold in nonprogressors.
TP was identified as themajor risk factor for scarring progression in our previous analysis
(9); therefore, the analyses described above were repeated using TP as the primary
outcome. In random effects linear regression models, all genes, with the exceptions of
TGFB1 and MMP7, had evidence of an association with TP (Table S1); the three most
strongly upregulated genes were CXCL13, CCL18, and S100A7, and the three most
downregulated genes were SPARCL1, MUC7, and MUC5AC. Lasso regression was per-
formed to identify the genes most strongly associated with TP (Table S2). The final
iteration of the model only excluded three genes not deemed to be associated with TP,
namely, MMP7, MUC1, and NCAM1. Age and C. trachomatis infection status but not sex
TABLE 1 Number of individuals for which gene expression data were available at each of
the study time points, with C. trachomatis infection and TP statuses
Time
point
No. of
participants
sampled
No. (%) witha:
C. trachomatis infection TP
1 506 78 (15.4) 99 (19.6)
2 536 82 (15.3) 107 (20)
3 466 54 (11.6) 68 (14.6)
4 466 6 (1.3) 10 (2.1)
5 477 12 (2.5) 35 (7.3)
7 472 21 (4.4) 14 (3)
9 450 12 (2.7) 12 (2.7)
11 426 45 (10.6) 12 (2.8)
13 444 33 (7.4) 13 (2.9)
15 380 49 (12.9) 20 (5.3)
17 426 21 (4.9) 14 (3.3)
aThe absolute number of participants in which C. trachomatis or TP was detected at each time point is
shown; chronic and new infections in the same or different children are not differentiated.
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were included in the final model. The genes whose expression was most strongly
associated with TP were MZB1, MMP9, CXCL5, PDGFB, TGFB1, IL17A, S100A4, IL8, S100A7,
SPARCL1, and IDO1. In order to investigate whether individuals prone to TP (TP was
detected at any time point) responded differently to C. trachomatis infection than
individuals not prone to TP (in whom TP was never detected throughout the study
duration), random effects linear regression models were repeated and included an
interaction term between infection and whether any TP was detected. In individuals
prone to TP, evidence was found that the expression of PDGFB, S100A7, IL23A, IL8,
MMP9, CCL2, IL19, CCL18, and IL6 was upregulated, and the expression of MUC7, IDO1,
S100A4, and MMP7 was downregulated in response to C. trachomatis infection, relative
to individuals in which TP was never detected (Table S3A). Of these 13 genes, only
S100A7 had a fold change greater than 1.5. Stratum-specific fold changes are shown
in Table S3B.
DISCUSSION
In this study, we measured the expression of 46 immune response genes at 11 time
points over a 4-year period, analyzing gene expression in relation to 4-year scarring
progression status and pathological TP. The genes found to be associated with scarring
progression included those encoding proinflammatory chemokines (CXCL5, CCL20,
CXCL13, and CCL18), cytokines (IL23A, IL19, and IL1B), matrix modifiers (MMP12 and
SPARCL1), immune regulators (IDO1, SOCS3, and IL10), and a proinflammatory antimi-
crobial peptide (S100A7). All genes except SPARCL1 were upregulated. A summary of
the putative functions and interactions of these immune mediators is shown in Fig. 1.
 
Scarring
↑ MMP12
↑ IL19
↑ CXCL13
↑ IL10
↑ SOCS3
↑ IDO1
↑ CCL18
↓ SPARCL1
PMNB
Th17
T
T
APC
↑ IL23A
Inflammatory cell 
infiltration
C. Trachomatis infection
23A 
RC
23A 
RC
Pro-inflammatory epithelium
X
X
X
↑ CCL20
↑ S100A7
↑ CXCL5
↑ IL1B
↑ PDGFB
FIG 1 Graphical summary of the genes associated with progressive scarring trachoma and hypothesized molecular
pathways of pathogenesis. In response to C. trachomatis infection, scarring progressors had higher expression of
IL23A and PDGFB than nonprogressors, suggesting a bias toward Th17 or other IL-23A-responsive cells (23A RC) and
increased fibrosis. The association of increased proinflammatory epithelial (CXCL5, CCL20, CXCL13, IL19, IL1B, and
S100A7) and dendritic cell-derived signals (CCL18, IL23A, and IL19) in scarring trachoma is indicative of ongoing
epithelial inflammation and continued bias toward IL-23A-responsive cell types, which could form proinflammatory
feedback cycles. These responses could be aggravated by external stimuli. Upregulation of the inflammatory
regulators IL10, IDO1, and SOCS3 supports the presence of chronic or uncontrolled inflammation. Matrix factors
MMP12, SPARCL1, and PDGFB may be acting as direct mediators of fibrosis.
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SPARCL1 had the greatest fold change and was the gene most strongly associated
with scarring progression in this study. It was also strongly associated with TP and C.
trachomatis infection. The downregulation of SPARCL1 has previously been reported to
be associated with trachomatous scarring and inflammation (2, 4, 11). SPARCL1 is a
nonstructural secreted protein that regulates the interaction between cells and the
extracellular matrix (ECM). Its downregulation has been associated with cell prolifera-
tion and metastases in several cancers (12, 13). Knockout of SPARCL1 in a murine
corneal injury model led to the accumulation of inflammatory infiltrates, neovascular-
ization and irregular ECM deposition at the site of injury (14). In contrast to wild-type
mice, in which matrix metallopeptidase (MMP) activity was increased shortly after injury
and then stabilized, MMP activity (detected through collagenase assay) was signifi-
cantly greater in knockout mice, and activity increased throughout the duration of the
experiment. This increased MMP activity was attributed to the excessive production of
irregular collagen (14). MMP12, which is produced by monocytes, ocular epithelial cells,
and fibroblasts following injury, was also significantly upregulated in scarring progres-
sors in this study, andMMP9 was strongly associated with TP. In another murine corneal
injury model, MMP12 was found to enhance early wound repair through increasing
neutrophil infiltration and epithelial cell migration, suggesting that overexpression in
trachoma might contribute to leukocyte infiltration (15). Histological analysis of con-
junctival tissue from trichiasis patients has revealed inflammatory cell infiltrates and
disrupted collagen structure consistent with the SPARCL1 knockout corneal injury
model (14, 16, 17).
The chemokines CXCL5, CCL20, CXCL13, and CCL18, derived from epithelial and
antigen-presenting cells on exposure to microbial stimuli and proinflammatory cyto-
kines, recruit lymphocytes and neutrophils. IL-1 and S100A7 are innate proinflamma-
tory mediators that are upregulated in the epithelium upon microbial exposure;
S100A7 has antimicrobial and chemotactic properties (18). CXCL5, CCL18, IL1B, and
S100A7 have consistently been found to be associated with trachomatous inflammation
and scarring (2, 8, 11, 19–22). The upregulation of these chemokines and proinflam-
matory mediators is indicative of ongoing inflammation in the conjunctival epithelium
and the recruitment and activation of neutrophils and lymphocytes. The overexpression
of these immune mediators in scarring progressors after adjusting for C. trachomatis
infection could reflect differences in exposure to other microbes or to irritants such as
dust or smoke (23, 24). The strong association of S100A7, IL8, and CXCL5 with TP
emphasizes the importance of innate epithelial responses in driving pathological
inflammation.
The association of scarring progression with IDO1, SOCS3, and IL10, all of which are
regulators of inflammation, is likely a result of the host’s attempts to limit ongoing and
pathological inflammation. While this may reflect that these individuals experienced
greater inflammation than nonprogressors, it could also suggest that scarring progres-
sors produce an excess of anti-inflammatory factors, leading to a poorer ability to clear
infection. Genetic polymorphisms in interleukin 10 (IL-10) that lead to increased
cytokine production and diminished cell-mediated immune responses to C. trachomatis
have previously been reported (25, 26). However, in this scenario, one might expect the
expression of these immune regulators to be increased in response to C. trachomatis
infection in scarring progressors relative to that in nonprogressors, which was not the
case.
IL23A and IL19 were upregulated in individuals with scarring progression. IL23A was
also upregulated in response to C. trachomatis infection in individuals with scarring
progression and those prone to TP. IL-23A is a proinflammatory cytokine that is largely
produced by dendritic cells and is essential for the survival and expansion of IL-17-
producing Th17 cells (27). In this study, IL17A was strongly associated with TP but not
with scarring progression. Furthermore, IL21, which was strongly upregulated in re-
sponse to C. trachomatis infection (and to a lesser extent to TP), is an autocrine factor
that sustains Th17 cells (28). Psoriasis is an autoimmune disease characterized by
excessive cytokine production that is triggered by environmental stimuli on a back-
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ground of genetic susceptibility (29). In psoriasis, keratinocytes recruit dendritic cells via
CCL20, and the production of IL-23A by keratinocytes and dendritic cells recruits and
activates IL-17A-producing Th17 cells, CD8 T cells, innate lymphoid cells (ILC), and 
T cells (30). IL-19 is produced by monocytes and epithelial cells and is also strongly
upregulated in the keratinocytes of psoriasis patients (31, 32). IL-19 has been proposed
as a member of the inflammatory IL-23A/IL-17A cascade in psoriasis; its upregulation in
keratinocytes is driven by IL-17A, and it acts in an autocrine fashion on keratinocytes to
amplify the effects of IL-17A (31). One such effect is the induction of S100A7 produc-
tion, which contributes to sustaining the cycle of inflammation (33). In the intestine,
IL-23A is thought to act synergistically with IL-1 to promote pathogenic ILC and Th17
responses following infection with Helicobacter hepaticus (34). IL-23A-responsive ILCs
were also found to mediate intestinal pathology in a murine colitis model (35), and
IL-1-responsive IL-17A-producing ILCs have been reported in the conjunctiva (36).
Together, these data suggest that the overexpression in scarring trachoma of CCL20,
IL23A, IL19, IL1B, and S100A7 could reflect mechanisms of pathogenesis similar to those
observed in psoriasis and intestinal inflammation, whereby the upregulation of IL23A
and IL1B promotes the recruitment and activity of pathogenic IL-23A-responsive cells
(Th17, ILC, or  T cells, for example), which drive proinflammatory responses in the
conjunctival epithelium, leading to chronic inflammation and fibrosis. The upregulation
of IL23A in scarring progressors and TP-prone individuals in response to C. trachomatis
infection could also suggest that greater polarization toward pathological IL-23A-
responsive cell types could be involved in initiating and sustaining pathological pro-
inflammatory cycles in the epithelium. Evidence from murine models suggests that
chlamydial antigens can be maintained in distal tissues such as the gut for long periods
of time (37), which could offer an additional explanation for prolonged inflammation
through the continued stimulation of circulating cells.
PDGFB was upregulated in response to C. trachomatis infection in scarring progres-
sors relative to nonprogressors; however, it was not independently associated with
scarring progression. PDGFB is a key mediator of the wound-healing process; it can
promote the recruitment and activity of neutrophils, fibroblasts, and macrophages, and
it induces the production of matrix molecules from fibroblasts and induces fibroblast
and myofibroblast contraction (38, 39). PDGFB could therefore directly contribute to
scarring progression. PDGFB was upregulated in response to C. trachomatis infection
and TP and was one of the genes most strongly associated with TP. The lack of direct
association between scarring progression and PDGFB in a model adjusting for infection
could indicate that its upregulation is tightly correlated with the presence of infection.
The reason for its upregulation alongside IL23A in scarring progressors in response to
C. trachomatis relative to expression in nonprogressors is unclear. A genome-wide
association study of scarring trachoma suggested that host cell cycle, cell surface
receptor signaling, and immune response pathways were associated with scarring,
although no specific cytokine risk loci were identified (40).
The strengths of this study lie in the large sample size and the use of 11 longitudinal
time points at which high-quality gene expression, infection, and clinical data are
available. Of the genes associated with scarring progression, most had marginal fold
changes of 1.4; however, small differences in multiple genes could act synergistically
to favor pathological pathways (34). Although mucinsMUC7 andMUC5ACwere strongly
downregulated in response to infection, consistent with our results at baseline (4), we
found little evidence in this study for dysregulation of mucins (hypothesized to lead to
loss of epithelial barrier function) being associated with scarring progression. Support-
ing previous results from ourselves and others (4–6), IFNG was strongly upregulated in
response to infection but was not associated with scarring progression (and was not
strongly associated with TP), suggesting that a Th1-cell or NK-cell IFN- response is
beneficial in the clearance of C. trachomatis infection. Upregulation of IL21 and IL17A
was strongly associated with infection and female sex, suggesting the involvement of
Th17 cells in the antichlamydial immune response and that Th17 cell responses might
be heightened in females relative to those in males. Sex differences in immune
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responses have previously been reported, including an increase in Th17 responses in
the intestinal mucosa of females (41, 42). Given the potential role of the IL-23A/IL-17
axis in trachoma pathogenesis, this could offer a potential explanation as to why
females are at greater risk of scarring trachoma than males (3). The majority of the
genes tested were upregulated in younger participants, probably reflecting the decline
in infection and disease incidence with increasing age. A caveat of this study is that
gene expression data do not necessarily translate to changes in effector responses, and
further research should aim to identify functional pathways of trachoma pathogenesis,
including the phenotype and function of the cells responding to IL23A. We previously
reported that mass azithromycin distribution (MDA) had an anti-inflammatory effect on
conjunctival gene expression independent of the clearance of C. trachomatis infection,
which was detectable by 3 (but not by 6) months posttreatment (10). However, analysis
of the impact of MDA on gene expression in relation to scarring progression and
whether it has a protective effect was outside the scope of this study.
Conclusions. Collectively, these data suggest that innate proinflammatory signals
from the epithelium that drive leukocyte infiltration, IL-23A-responsive cells, and
SPARCL1-, MMP12-, and PDGFB-mediated matrix reorganization and contraction are key
pathways driving trachomatous scarring sequelae. The factors driving innate epithelial
inflammation and causing scarring progressors to produce more IL23A and PDGFB in
response to C. trachomatis infection remain unclear; they could have underlying
genetic or epigenetic bases and/or be due to the presence of other organisms or
irritants influencing the local immune response (43, 44). However, despite several
studies, thus far there is limited evidence for any major infectious or genetic risk factors
(40, 45). One could speculate that a complex combination of genetic or infectious risk
factors increases an individual’s susceptibility, such that upon the trigger of C. tracho-
matis infection, individuals possessing these risk factors develop a bias toward patho-
logical IL-23A-responsive cells, which lead to sustained proinflammatory responses in
the conjunctival epithelium that are exacerbated by other stimuli. The concept of
infectious triggers causing sustained inflammation and fibrosis has been illustrated in
the intestinal epithelium, with a number of distinct molecular pathways (46). Further
research should seek to verify these pathways of trachoma immunopathogenesis at the
functional level. Nevertheless, IL23A, SPARCL1, and PDGFBmay be key mediators driving
pathological inflammation and fibrosis in trachoma, and molecules that inhibit their
action could hold therapeutic potential in preventing scarring progression.
MATERIALS AND METHODS
Ethical approval. This study was reviewed and approved by the Tanzanian National Institute for
Medical Research, the Kilimanjaro Christian Medical Centre, and the London School of Hygiene & Tropical
Medicine Ethics Committees and it adhered to the tenets of the Declaration of Helsinki. Written informed
consent from a parent or legal guardian was requested from all study participants after detailed
explanation in Swahili or Maa in the presence of a third person. A witnessed thumbprint was acceptable
for consent if the individual was unable to read or write.
Study design and trachoma control. Study participants were recruited from three rural and
predominantly Maasai villages in northern Tanzania. The study design and population have been
described in detail in several earlier reports (4, 9, 10). In brief, a cohort of 616 children, aged 6 to 10 years
at the beginning of the study in February 2012, were enrolled in the longitudinal cohort study and were
visited every 3 months for 4 years, for a total of 17 time points.
The SAFE strategy (surgery for trichiasis [in-turned eyelashes], antibiotics, facial cleanliness, and
environmental improvement) was implemented in the study villages by the field team in collaboration
with district eye coordinators, following approval from the Tanzanian Ministry of Health (MoH). Education
about environmental improvements and facial hygiene was provided by the field team, free trichiasis
surgery was offered, and all members of the three villages (including study participants) were offered
azithromycin for trachoma control during the August of the years 2012, 2013, and 2014.
Clinical examination and sample collection. At each time point, all available and consenting cohort
participants were examined. Eyes were initially anaesthetized using preservative-free proxymetacaine
hydrochloride 0.5% eyedrops. Each participant’s left eyelid was everted, and the tarsal conjunctiva was
examined by an ophthalmic nurse experienced in trachoma grading using 2.5 loupes and a torch.
Clinical signs were graded using the WHO detailed FPC grading system (47). Using the FPC grading
system, F2/F3 corresponds to “trachomatous inflammation—follicular” (TF) and P3 corresponds to
“trachomatous inflammation—intense” (TI) of the WHO simplified grading system (48). We consider P2
to also represent significant clinically apparent inflammation, and we therefore refer to P2/P3 as “TP” and
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use this designation in all analyses (2, 9, 10). At each time point, high-resolution conjunctival photo-
graphs were taken with a Nikon D90 camera with a 105-mm macro lens.
At baseline (time point 1, or time point 2 if not seen at time point 1) and final time points (time point
17, or time point 16 if not seen at time point 17), conjunctival photographs were independently graded
by an ophthalmologist using a detailed scarring grading system (49). Baseline and final photographs for
each individual were subsequently compared side by side in order to determine whether there was no
progression (no scarring, or no progression of existing scarring) or incidence/progression of trachoma-
tous scarring. Participant entry into the longitudinal study was permitted at time points 1 and 2, after
which no new participants were enrolled.
At each time point swab samples were collected from the left tarsal conjunctiva using sterile
polyester-tipped swabs (Puritan), as described previously (4). The first swab was collected into 250 l
RNAlater (Invitrogen), and the second was stored dry. Swabs were stored on ice in the field. RNAlater
swabs were stored at 2 to 8°C overnight before transfer to 80°C for long-term storage. Dry swabs were
stored immediately at 80°C.
Chlamydia trachomatis detection. At time point 1, DNA was extracted from dry-stored swabs using
a PowerSoil DNA isolation kit (Mo Bio Laboratories), and this DNA was used for C. trachomatis detection
by droplet digital PCR (ddPCR), as described previously (4). At time points 2 through 17, RNA and DNA
were extracted from RNAlater-stored swabs using RNA/DNA purification kits (Norgen Biotek) following
the manufacturer’s instructions, and this DNA was used for C. trachomatis detection by quantitative PCR
(qPCR) (9, 10). Triplex qPCR was performed targeting chlamydial chromosomal (omcB) and plasmid
(pORF2) targets and a human endogenous control gene (RPP30) (50). Samples were tested in duplicate
and were determined positive if RPP30 in combination with pORF2 and/or omcB targets amplified for40
cycles in one or both replicates. Norgen-extracted DNA from time point 2 was tested by qPCR and ddPCR
for the C. trachomatis plasmid target for comparison, and the kappa score for agreement was 0.84 (10).
Gene expression. Norgen-extracted RNA from time points 1 to 5, 7, 9, 11, 13, 15, and 17 was reverse
transcribed using SuperScript VILO cDNA synthesis kits (Thermo Fisher Scientific) following the manu-
facturer’s instructions. The relative abundances of 48 genes of interest, including those of GAPDH and
HPRT1 endogenous control genes, were quantified in each sample by qPCR using TaqMan microfluidic
384-well array cards (Thermo Fisher Scientific). qPCR was performed on a ViiA7 thermal cycler with
TaqMan Universal mastermix, as described previously (4). The 46 genes of interest were shortlisted from
a total of 91 genes tested at time point 1 (4), based on those most strongly associated with C. trachomatis
infection and/or clinical signs. The original 91 genes were selected based on the results of previous
cross-sectional studies and were centered around key biological processes hypothesized to underlie the
immunopathogenesis of trachoma, including antimicrobial peptides, cell cycle regulators, cytokines and
chemokines, biomarkers of epithelial-mesenchymal transition, matrix modifiers, the response to micro-
biota, mucins, NK cell markers, pattern recognition receptors, and signaling pathway regulators.
Analysis. Data were stored in Microsoft Access and were analyzed in STATA v15 and R (www.R
-project.org). Gene expression data were normalized using the cycle threshold (ΔCT) method (51),
normalizing the expression of each gene to the expression of HPRT1 in the same sample. For quality
control purposes, both genes and observations (defined as a sample from a participant at one time point)
with 10% missing data were excluded. This resulted in the exclusion of three genes (FGF2, SERPINB3-
SERPINB4, and IL22) and 61/4,853 observations, leaving 4,792 observations and 43 genes of interest
(excluding HPRT1 and GAPDH) in the analysis.
In order to assess the association between longitudinal gene expression and scarring progression,
random effects linear regression models were performed for each gene in turn, using gene expression
as the dependent variable and adjusting for infection, age, and sex, clustering on participant ID. These
analyses were subsequently repeated for TP, adjusting for infection, age, and sex.
Random effects lasso regression models using the glmmLasso package in R (52) were used to select
the genes most strongly associated with scarring progression and TP. This analysis does not permit any
missing data, and therefore only complete cases were retained from the filtered data set described
above. This resulted in a data set of 3,622 observations and 43 genes for the scarring progression analysis
and a data set of 4,510 observations and 43 genes of interest for the TP analysis. Age, sex, and infection
were adjusted for in each model.
In order to determine whether scarring progressors responded differently from nonprogressors to C.
trachomatis infection at the gene expression level, the random effects linear regression analyses
described above were repeated, including an interaction term between scarring progression status and
C. trachomatis infection. These analyses were further repeated to investigate whether individuals prone
to TP (defined as those who had TP at any time point) responded differently to infection relative to
individuals in whom TP was never detected throughout the study duration. To provide an objective
threshold for reporting the genes most strongly associated with the outcome, we highlight those genes
with a P value below the level that controls the false discovery rate (FDR) to be less than 5%, using the
Benjamini-Hochberg method (53).
Data availability. The longitudinal gene expression data set can be accessed on Figshare (https://
doi.org/10.6084/m9.figshare.11401158.v1).
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